Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

T. I. Verhoef; W. K. Redekop; S. Langenskiold; F. Kamali; M. Wadelius; G. Burnside; A.-H. Maitland-van der Zee; D. A. Hughes; M. Pirmohamed

doi:https://doi.org/10.1038/tpj.2016.41

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

T. I. Verhoef, W. K. Redekop, S. Langenskiold, F. Kamali, M. Wadelius, G. Burnside, A.-H. Maitland-van der Zee, D. A. Hughes, M. Pirmohamed

Pulmonology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

Abstract

We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were 26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were 6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of 20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden

Original language	English
Pages (from-to)	478-484
Journal	pharmacogenomics journal
Volume	16
Issue number	5
DOIs	https://doi.org/10.1038/tpj.2016.41
Publication status	Published - 2016

Access to Document

https://doi.org/10.1038/tpj.2016.41

Cite this

@article{60613218a5d84564bb52d9a8bd85cb54,

title = "Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden",

abstract = "We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were 26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were 6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of 20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden",

author = "Verhoef, {T. I.} and Redekop, {W. K.} and S. Langenskiold and F. Kamali and M. Wadelius and G. Burnside and {Maitland-van der Zee}, A.-H. and Hughes, {D. A.} and M. Pirmohamed",

year = "2016",

doi = "https://doi.org/10.1038/tpj.2016.41",

language = "English",

volume = "16",

pages = "478--484",

journal = "pharmacogenomics journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

AU - Verhoef, T. I.

AU - Redekop, W. K.

AU - Langenskiold, S.

AU - Kamali, F.

AU - Wadelius, M.

AU - Burnside, G.

AU - Maitland-van der Zee, A.-H.

AU - Hughes, D. A.

AU - Pirmohamed, M.

PY - 2016

Y1 - 2016

N2 - We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were 26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were 6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of 20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden

AB - We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were 26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were 6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of 20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden

U2 - https://doi.org/10.1038/tpj.2016.41

DO - https://doi.org/10.1038/tpj.2016.41

M3 - Article

C2 - 27272045

SN - 1470-269X

VL - 16

SP - 478

EP - 484

JO - pharmacogenomics journal

JF - pharmacogenomics journal

IS - 5

ER -